The injectables: a new silver bullet?
|
|
- Clare Walker
- 6 years ago
- Views:
Transcription
1 The injectables: a new silver bullet? Geneva October 6 Francois Venter Wits Reproductive Health and HIV Institute Thanks Clinical Care Options, Helen Rees, Joe Eron, Wits RHI sex worker team
2 Disclosures Part of optimisation collaborations grants to improve testing, new drug regimens, linkage to care Pharma (including drug donations for studies) and managed care
3 The silver bullet For ART treatment and PrEP Note: benefits in most of medicine is incremental
4
5 LATTE-: Cabotegravir IM + Rilpivirine IM for Long-Acting Maintenance ART Multicenter, open-label phase IIb study Cabotegravir: integrase inhibitor Induction Phase* Maintenance Phase Wk primary analysis Wk 6: RPV Wk PO added Wk ART-naive HIVinfected pts with CD4+ cell count > cells/mm (N = 9) Wk 96 CAB 4 mg IM + RPV 6 mg IM Q4W (n = 5) CAB mg PO QD + ABC/TC CAB 6 mg IM + RPV 9 mg IM Q8W (n = 5) CAB mg PO + ABC/TC PO QD (n = 56) 6 pts discontinued for AEs or death in induction analysis. *Pts with HIV- RNA < 5 c/ml from Wk 6 to Wk continued to maintenance phase. Loading dose: Day, CAB 8 mg + RPV 6 mg. Loading dose: Day, CAB 8 mg + RPV 9 mg; Wk 4, CAB 6 mg. Margolis DA, et al. CROI 6. Abstract LB. Slide credit: clinicaloptions.com
6 LATTE-: Wk Efficacy and Safety HIV- RNA <5 c/ml (%) Treatment Differences (95% CI): Q4W IM vs Oral:.8 (-5.8 to.5) Q8W IM vs Oral:.7 (-4.8 to.) Most frequent ISRs were pain (67%), swelling (7%), and nodules (6%) IM CAB + RPV Q4W (n = 5) IM CAB + RPV Q8W (n = 5) Oral CAB + ABC/TC (n = 56) 8 6 ISR events/injection:.5 99% of ISRs grade /; none grade 4 % of pts withdrew for ISRs 4 Oral Arm (n = 56) Drug-related grade /4 AEs (excluding ISRs) Serious AEs 6 5 AEs leading to withdrawal AEs, % Pooled IM Arms (n = ) < 4 Virologic Success 4 Virologic Nonresponse 5 < 5 No Virologic Data No INSTI, NNRTI, or NRTI resistance mutations detected Margolis DA, et al. CROI 6. Abstract LB. Slide credit: clinicaloptions.com
7 LATTE-: Wk Pt Satisfaction With Maintenance Therapy vs Oral Induction How satisfied are you with your current treatment? (vs oral induction treatment) More Neutral Pts (%) Less Neutral Less More 8 How satisfied would you be to continue with your present form of treatment? (vs oral induction treatment) Q8W (n = 6) Q4W (n = ) Oral CAB (n = 49) Margolis DA, et al. CROI 6. Abstract LB Q8W (n = 6) Q4W (n = ) Oral CAB (n = 49) Slide credit: clinicaloptions.com
8 Other Potential Long-Acting ARVs Agent MoA Study results MK-859 (EFdA) NRTI[] Phase I study: treatment-naive pts, single -mg dose (N = 6) Mean t/: 8 hrs Mean VL reduction at days postdose:.78 log BNC7, VRC Broadly neutralizing antibodies (bnabs) BNC7: single infusion reduced VL up to.5 log (n = 7); mean t/: 9 days[] VRC: single infusion reduced VL up to.8 log in treatment-naive pts (n = 8); minimal responders exhibited resistant virus at BL[]. Friedman EJ, et al. CROI 6. Abstract 47LB.. Caskey M, et al. Nature. 5;5: Lynch RM, et al. Sci Transl Med. 5;7:9ra6. Slide credit: clinicaloptions.com
9 And nanoparticles.
10 Concerns?breakthrough on PrEP may lead to prolonged exposure to drug, accumulating resistance Serious side effects means lead-in dose
11 But. What problem are we trying to fix?
12 Adherence issues generally? But PrEP adherence ins some groups >9% And treatment improving Thanks Joe Eron
13 Improved outcomes may be more dependent on social support than new drugs Thanks: Simon Collins
14 And special populations? TAPS project adherence superb to ART and PrEP IDUs? Similarly if support them, they take their treatment and PrEP Psychiatric, adolescent, chaotic patients
15 Clinics in central Johannesburg Thanks to Sam Lalla-Edwards and team, M&E Dept, RHI First and Second line regimens at ART initiation for Jan to Dec 5 Facility name JAN HCHC Yeoville 8 Albert Jeppe Clinic Joubert Park Rosettenville Malvern Jeppe Street Bellavista Crown Gardens Mayfair Bezvalley Glenanda SRH South Hills Kibler Park CMJAH FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC TOTAL INITIATIONS st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line st Line nd Line 6
16 First and Second line regimens at ART initiation for Jan to Dec 5 FEB M A R APR MAY JUN JUL AUG SEP OCT NOV DEC TOTAL INITIATIONS
17 Thanks: Andrew Hill In press, SAMJ
18 ART is starting to look increasingly like contraception Oral, injectables, implantables, rings. Interesting to examine the history slow and steady move towards more long acting agents But: breakthrough pregnancies ESPECIALLY if no reminders/ support
19 Injectables are exciting But we must be careful about what problem we are fixing Complex if a lead-in oral dose Will not cure bad health systems Need lots of real world and adherence research Lessons from the contraceptive world
20
21
Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationLong Acting ART for Treatment and PrEP
Long Acting ART for Treatment and PrEP Anton Pozniak MD FRCP Consultant Physician Disclosures I have received honoraria, travel sponsorship and research grants from: Gilead Sciences Janssen MSD ViiV Healthcare
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationTaking a shot at HIV with longacting injectable ARVs for treatment and prevention
Taking a shot at HIV with longacting injectable ARVs for treatment and prevention Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron Diamond AIDS Research Center Aaron Diamond Professor
More informationPrEP: Is Longer Better? Myron S. Cohen, MD
PrEP: Is Longer Better? Myron S. Cohen, MD Yeargan-Bate Eminent Professor Medicine, Microbiology and Epidemiology Director, Institute for Global Health & Infectious Diseases TDF/FTC was FDA Approved for
More informationv Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis
18 th Annual Resistance and Antiviral Therapy Meeting v Dr Anton Pozniak Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London Injectable ARVs a S.W.O.T
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationInvestigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents
Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents Joseph J. Eron MD Professor of Medicine University of North Carolina Chapel Hill, North Carolina Learning Objectives
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationFuture Perspectives for Delivery of Antiretroviral Drugs
Future Perspectives for Delivery of Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More information4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections
Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine
More information11/7/2016. Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama
HIV Preexposure Prophylaxis: Pills, Rings, Injectables, and Gels Oh My! Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FORMATTED: 10/17/16 Financial
More informationAntiretroviral Therapy Where we are and where we are going
Antiretroviral Therapy Where we are and where we are going Joe Eron, MD Professor Medicine UNC Chapel Hill February 2016 Disclosures Dr. Eron received research grants awarded to his institution from AbbVie,
More informationRoy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationSimplified regimens: Pros and Cons
Rio de Janeiro, 2018 Simplified regimens: Pros and Cons Pedro Cahn Treatment Strategies: A long way Monotherapy Dual therapy STIs Triple therapy Non daily regimens Simplification Mega HAART Long Acting/Extended
More informationDebating view on less ART. Strategies under evaluation
Debating view on less ART Strategies under evaluation Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena Department of Infectious Diseases, Siena University Hospital, Italy Conflicts
More informationViiV Healthcare Investor and Analyst Update 24 July 2018
ViiV Healthcare Investor and Analyst Update 24 July 2018 Cautionary statement regarding forward looking statements This presentation may contain forward-looking statements. Forward-looking statements give
More informationCROI 2016: Top Ten for Clinicians
Hynes Convention Center. Boston, MA; US. Feb 22-25, 2016 CROI 2016: Top Ten for Clinicians Josep M Llibre Hospital Universitari Germans Trias i Pujol Fundació Lluita contra la SIDA Badalona, Barcelona
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationHIV-Therapie: Injectables und Generika. Priv.-Doz. Dr. Christoph D. Spinner
HIV-Therapie: Injectables und Generika Priv.-Doz. Dr. Christoph D. Spinner Potentielle Interessenskonflikte PD Dr. med. Christoph D. Spinner Beratungstätigkeit und Vortragstätigkeit gegen Honorar sowie
More informationHIV IS NOT OVER. Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Learning Objectives
Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Davey M. Smith, MD, MAS Professor of Medicine University of California San Diego San Diego, California Learning Objectives
More informationLong-acting Treatment with Antiretrovirals
Long-acting Treatment with Antiretrovirals Saye Khoo, University of Liverpool, UK Declaration of Interests www.hiv-druginteractions.org & www.hep-druginteractions.org Receives sponsorship from AbbVie,
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationDr Marta Boffito 15/10/ th Annual Resistance and Antiviral Therapy Meeting. Chelsea and Westminster Hospital, London
18 th Annual Resistance and Antiviral Therapy Meeting Dr Marta Boffito Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London 1 virological response (SVR)
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationThe pipeline: Long-acting agents and new drugs. Charles Flexner, MD Johns Hopkins University
The pipeline: Long-acting agents and new drugs Charles Flexner, MD Johns Hopkins University Do we still need an ARV pipeline? How close are we to having a universal antiretroviral regimen? A universal
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More information5/2/2016. Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion
Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion Joseph J. Eron, Jr, MD Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina FORMATTED: 4/13/216
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationNew Delivery Systems and Long Acting Antiretroviral Drugs
New Delivery Systems and Long Acting Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Prague October 2018 Disclosures Honoraria received for advisory boards
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationImproving care of HIV-infected breastfeeding
Improving care of HIV-infected breastfeeding and their : Early results from the Partnership for HIV-free Survival Initiative in Uganda Tamara Nsubuga-Nyombi, URC IAS- Melbourne, Australia July 22nd, 2014
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationLong-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
More informationSTRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationNew Drugs in Development Are We Ready for Long-Acting ART?
New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD Principal Investigator AIDS Research Consortium of Atlanta Atlanta, Georgia Learning Objectives After attending this presentation,
More informationDolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationLong Acting HIV Drugs for Prevention: what are the data? Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint
Long Acting HIV Drugs for Prevention: what are the data? Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint DISCLOSURES I have received a research grant from Gilead Sciences
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationTreatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017
Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Conflicts of interest Receive
More informationReport Back: HIV Treatment Updates
Report Back: HIV Treatment Updates Catherine Koss, MD Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General Hospital University of California, San
More informationBHIVA Best of CROI Feedback Meetings
BHIVA Best of CROI Feedback Meetings London Birmingham Haydock Newcastle Cardiff Wakefield Edinburgh BHIVA Best of CROI Feedback Meetings 2016 New drugs Dr David Asboe Chelsea and Westminster Hospital,
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationDidactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15
Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationNuevos fármacos an/retrovirales
Nuevos fármacos an/retrovirales Pere Domingo Malal/es Infeccioses Hospitals Universitaris Arnau de Vilanova & Santa María IRB Lleida Universitat de Lleida pdomingo@gss.scs.es La escasez persiste... Combinec/n:
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationTwo-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine
Two-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine T, Yoshinaga, S. Miki, T. Seki, T. Fujiwara Shionogi & Co., Ltd., Osaka, Japan Background A two-drug regimen may
More informationHIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE
HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE Site C Youth clinic HIV care pathway DAY 1 Test HIV + PIMA point of care CD4 count in in 3-5 days initiation + in session 3 session 4 1 month Youth Club
More informationCROI 2018 Update. Christian B. Ramers, MD, MPH, AAHIVS. Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego
CROI 2018 Update Christian B. Ramers, MD, MPH, AAHIVS Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego Assistant Clinical Professor UC San Diego School of Medicine
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More information10/05/2016. Long-Acting Antiretroviral Agents For Prevention. Dr Paul Benn MB ChB FRCP
Long-Acting Antiretroviral Agents For Prevention Dr Paul Benn MB ChB FRCP 1 Disclosures Paul Benn is a full time employee of ViiV Healthcare and an honorary HIV Consultant at the Mortimer Market Centre,
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationClinical Pharmacology Related Considerations.
Clinical Pharmacology Related Considerations. David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie, BMS,
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationQuality improvement efforts in Nigerian public health facilities
Quality improvement efforts in Nigerian public health facilities A presentation of FHI Nigeria at the maiden conference of the Society for Quality Healthcare in Nigeria 7 July, 2009 Dr Christoph Hamelmann
More informationIAC Analyst Presentation
IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%
More informationFGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS
AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationMcLean ebasis plus TM
McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More information